Los Angeles Capital Management & Equity Research Inc. cut its stake in shares of Stryker Corporation (NYSE:SYK) by 3.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,094 shares of the medical technology company’s stock after selling 1,127 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Stryker Corporation were worth $4,558,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Coldstream Capital Management Inc. boosted its position in Stryker Corporation by 3.7% during the second quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock valued at $2,421,000 after purchasing an additional 626 shares during the last quarter. Retirement Systems of Alabama boosted its position in Stryker Corporation by 2.5% during the third quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock valued at $33,356,000 after purchasing an additional 5,656 shares during the last quarter. Lockheed Martin Investment Management Co. acquired a new position in Stryker Corporation during the second quarter valued at approximately $1,249,000. Toronto Dominion Bank boosted its position in Stryker Corporation by 25.8% during the second quarter. Toronto Dominion Bank now owns 105,403 shares of the medical technology company’s stock valued at $14,625,000 after purchasing an additional 21,585 shares during the last quarter. Finally, Colonial Trust Advisors boosted its position in Stryker Corporation by 56.1% during the second quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock valued at $3,254,000 after purchasing an additional 8,426 shares during the last quarter. 74.20% of the stock is owned by hedge funds and other institutional investors.
Stryker Corporation (NYSE SYK) opened at $154.75 on Tuesday. Stryker Corporation has a 52 week low of $108.29 and a 52 week high of $160.62. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The company has a market capitalization of $58,156.52, a price-to-earnings ratio of 24.63, a price-to-earnings-growth ratio of 2.45 and a beta of 0.79.
Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the company earned $1.39 EPS. The company’s revenue was up 6.1% on a year-over-year basis. equities analysts forecast that Stryker Corporation will post 6.47 earnings per share for the current year.
WARNING: “Los Angeles Capital Management & Equity Research Inc. Sells 1,127 Shares of Stryker Corporation (SYK)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/11/21/los-angeles-capital-management-equity-research-inc-sells-1127-shares-of-stryker-corporation-syk.html.
Several analysts have issued reports on SYK shares. Royal Bank Of Canada restated a “buy” rating and issued a $155.00 price objective on shares of Stryker Corporation in a research note on Friday, September 1st. Argus restated a “buy” rating and issued a $160.00 price objective on shares of Stryker Corporation in a research note on Tuesday, August 29th. Zacks Investment Research lowered Stryker Corporation from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Cowen and Company set a $160.00 price objective on Stryker Corporation and gave the company a “buy” rating in a research note on Friday, October 6th. Finally, Stifel Nicolaus upped their price objective on Stryker Corporation from $158.00 to $168.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company. Stryker Corporation presently has a consensus rating of “Hold” and an average price target of $152.10.
In other Stryker Corporation news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the transaction, the insider now owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 7.40% of the stock is owned by company insiders.
Stryker Corporation Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.